Kommentar: ALK er kommer med 1. kvartalsregnskab for 2o21. Omsætninger runder 1. mia. DKK for første gang nogensinde for ALK. EBITDA steg med 14% til 226 mio. DKK. Det er specielt deres tablet portefølje, der viser stor vækst i Europa og Japan. Flot regnskab fra ALK
Forventninger til 2021:
ALK is updating its financial outlook for 2021 based on solid Q1 earnings, and a stronger full-year outlook for tablet sales, which is still partly offset by continuing uncertainty around COVID and its ongoing impact on sales of ALK’s legacy products. ALK assumes that patients’ ability and willingness to visit health care professionals will remain somewhat constrained in selected countries over the coming months. As a result:
- Revenue is now expected to grow 9-12% in local currencies (previously: 8-12), driven by tablet sales growth of ~25% (previously: >20%).
- EBITDA is now expected at DKK 375-425 million (previously: 325-425), benefiting from the improved tablet sales outlook. ALK still expects an increased gross margin, a significant increase in R&D expenses and a gradual normalisation of sales and marketing activities.
- Free cash flow is now expected at ~DKK minus 200 million (previously: minus 200-300) reflecting the revised earnings outlook.